These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 26944462)

  • 41. Ospemifene, a non-oestrogen selective oestrogen receptor modulator for the treatment of vaginal dryness associated with postmenopausal vulvar and vaginal atrophy: a randomised, placebo-controlled, phase III trial.
    Portman D; Palacios S; Nappi RE; Mueck AO
    Maturitas; 2014 Jun; 78(2):91-8. PubMed ID: 24679891
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pelvic floor muscles training to reduce symptoms and signs of vulvovaginal atrophy: a case study.
    Mercier J; Morin M; Lemieux MC; Reichetzer B; Khalifé S; Dumoulin C
    Menopause; 2016 Jul; 23(7):816-20. PubMed ID: 27219835
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Vaginal Health: Insights, Views & Attitudes (VIVA) - results from an international survey.
    Nappi RE; Kokot-Kierepa M
    Climacteric; 2012 Feb; 15(1):36-44. PubMed ID: 22168244
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Iranian postmenopausal women's experiences of treatment of symptomatic vulvovaginal atrophy.
    Fooladi E; Deldar M; Mohammadzadeh F; Ahmadnia E; Khani S; Ghanbari Z
    Climacteric; 2017 Feb; 20(1):67-71. PubMed ID: 28064523
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Low-dose, vaginally administered estrogens may enhance local benefits of systemic therapy in the treatment of urogenital atrophy in postmenopausal women on hormone therapy.
    Palacios S; Castelo-Branco C; Cancelo MJ; Vázquez F
    Maturitas; 2005 Feb; 50(2):98-104. PubMed ID: 15653006
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Sexual dysfunction in the peri- and postmenopause. Status of incidence, pharmacological treatment and possible risks. A secondary publication.
    Gregersen N; Jensen PT; Giraldi AE
    Dan Med Bull; 2006 Aug; 53(3):349-53. PubMed ID: 17092454
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Impact of vulvovaginal atrophy therapies on postmenopausal women's quality of life in the CRETA study measured by the Cervantes scale.
    Palacios S; Sánchez-Borrego R; Suárez Álvarez B; Lugo Salcedo F; González Calvo AJ; Quijano Martín JJ; Cancelo MJ; Fasero M
    Maturitas; 2023 Jun; 172():46-51. PubMed ID: 37099983
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The role of estrogens in female lower urinary tract dysfunction.
    Robinson D; Cardozo LD
    Urology; 2003 Oct; 62(4 Suppl 1):45-51. PubMed ID: 14550837
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Basic principles of hormone replacement therapy in the postmenopause].
    Dören M
    Ther Umsch; 2000 Oct; 57(10):628-34. PubMed ID: 11081374
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Vulvovaginal complaints.
    Mehta A; Bachmann G
    Clin Obstet Gynecol; 2008 Sep; 51(3):549-55. PubMed ID: 18677149
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Progress and prospects in treating postmenopausal vaginal atrophy.
    Winneker RC; Harris HA
    Clin Pharmacol Ther; 2011 Jan; 89(1):129-32. PubMed ID: 20944561
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A Randomized, Multicenter, Double-Blind, Study to Evaluate the Safety and Efficacy of Estradiol Vaginal Cream 0.003% in Postmenopausal Women with Vaginal Dryness as the Most Bothersome Symptom.
    Archer DF; Kimble TD; Lin FDY; Battucci S; Sniukiene V; Liu JH
    J Womens Health (Larchmt); 2018 Mar; 27(3):231-237. PubMed ID: 29193980
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Vaginal estrogen use and effects on quality of life and urogenital morbidity in postmenopausal women after publication of the Women's Health Initiative in New York City.
    Setty P; Rekedal L; Warren MP
    Menopause; 2016 Jan; 23(1):7-10. PubMed ID: 26263282
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Emerging hormonal treatments for menopausal symptoms.
    Genazzani AR; Komm BS; Pickar JH
    Expert Opin Emerg Drugs; 2015 Mar; 20(1):31-46. PubMed ID: 25557757
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Profile of ospemifene in the breast.
    Berga SL
    Reprod Sci; 2013 Oct; 20(10):1130-6. PubMed ID: 23945733
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Tissue-selective estrogen complexes for postmenopausal women.
    Mirkin S; Komm BS
    Maturitas; 2013 Nov; 76(3):213-20. PubMed ID: 23849704
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Sexual Health Matters: Management of Female Sexual Dysfunction.
    Vegunta S; Kling JM; Faubion SS
    J Womens Health (Larchmt); 2016 Sep; 25(9):952-4. PubMed ID: 27509374
    [No Abstract]   [Full Text] [Related]  

  • 58. Tissue selectivity of ospemifene: pharmacologic profile and clinical implications.
    Kangas L; Unkila M
    Steroids; 2013 Dec; 78(12-13):1273-80. PubMed ID: 24055829
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Women's voices in the menopause: results from an international survey on vaginal atrophy.
    Nappi RE; Kokot-Kierepa M
    Maturitas; 2010 Nov; 67(3):233-8. PubMed ID: 20828948
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Advances in menopausal therapy: the tissue-selective estrogen complex.
    Moore A
    J Am Assoc Nurse Pract; 2013 Mar; 25(3):126-33. PubMed ID: 24218199
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.